75 related articles for article (PubMed ID: 15922862)
21. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
[TBL] [Abstract][Full Text] [Related]
22. [The application of fluorescence in situ hybridization in detecting chronic myeloid leukemia].
Qiu HR; Miao KR; Wang R; Qiao C; Zhang JF; Zhang SJ; Qian SX; Xu W; Li JY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):207-10. PubMed ID: 19350518
[TBL] [Abstract][Full Text] [Related]
23. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
24. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
25. [Study of calcitonin gene methylation in chronic myeloid leukemia by using Hpa II-PCR].
Tan B; Cao P; Qi Z
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(4):371-3. PubMed ID: 12080652
[TBL] [Abstract][Full Text] [Related]
26. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
27. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
[TBL] [Abstract][Full Text] [Related]
28. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.
Galimberti S; Cervetti G; Guerrini F; Testi R; Pacini S; Fazzi R; Simi P; Petrini M
Cancer Genet Cytogenet; 2005 Oct; 162(1):57-62. PubMed ID: 16157201
[TBL] [Abstract][Full Text] [Related]
29. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
30. [Cytogenetic and molecular analysis of 1193 cases with chronic myeloid leukemia].
Jiang DZ; Chen ZM; Lou JY; Wang YG; Liang Y; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):1-5. PubMed ID: 17649716
[TBL] [Abstract][Full Text] [Related]
31. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
32. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE
Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567
[TBL] [Abstract][Full Text] [Related]
33. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
Soupir CP; Vergilio JA; Dal Cin P; Muzikansky A; Kantarjian H; Jones D; Hasserjian RP
Am J Clin Pathol; 2007 Apr; 127(4):642-50. PubMed ID: 17369142
[TBL] [Abstract][Full Text] [Related]
34. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
[TBL] [Abstract][Full Text] [Related]
35. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
Ruan GR; Qin YZ; Chen SS; Li JL; Ma X; Chang Y; Wang YZ; Fu JY; Liu YR
Leuk Res; 2006 Sep; 30(9):1159-65. PubMed ID: 16507320
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic regulation of PRAME gene in chronic myeloid leukemia.
Roman-Gomez J; Jimenez-Velasco A; Agirre X; Castillejo JA; Navarro G; Jose-Eneriz ES; Garate L; Cordeu L; Cervantes F; Prosper F; Heiniger A; Torres A
Leuk Res; 2007 Nov; 31(11):1521-8. PubMed ID: 17382387
[TBL] [Abstract][Full Text] [Related]
37. Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
Scrideli CA; de Oliveira FM; Brassesco MS; de Paula Queiroz R; Bernardes JE; Valera ET; Tone LG
Leuk Res; 2009 Mar; 33(3):495-9. PubMed ID: 18495245
[TBL] [Abstract][Full Text] [Related]
38. Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia.
Adler R; Viehmann S; Kuhlisch E; Martiniak Y; Röttgers S; Harbott J; Suttorp M
Eur J Haematol; 2009 Feb; 82(2):112-8. PubMed ID: 19067742
[TBL] [Abstract][Full Text] [Related]
39. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
40. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]